Compare Alnylam Pharmaceuticals, Inc. (ALNY) vs US Bancorp (USB) Price & Performance
Price performance
Price movement over the last 24 hours
Key statistics
Key statistics
Alnylam Pharmaceuticals, Inc. vs US Bancorp — how do they compare? Alnylam Pharmaceuticals, Inc. trades at $299.53 (market cap $39.89B), while US Bancorp trades at $62.61 (market cap $97.22B). The key difference: US Bancorp is far larger — about 2.4× Alnylam Pharmaceuticals, Inc.'s market cap, and US Bancorp pays a 3.33% dividend while Alnylam Pharmaceuticals, Inc. pays none. Which is the better fit depends on your goals.
| ALNY | USB | |
|---|---|---|
Market Cap | $39.89B | $97.22B |
Sector | Health | Financials |
52-Week High | $491.22 | $62.89 |
52-Week Low | $278.09 | $43.94 |
Enterprise Value | $38.15B | — |
Dividend Yield | — | 3.33% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
ALNY trades at $298.76, down 4.49% today, but maintains a bullish technical outlook with strong support at $290. The company reported robust revenue growth to $3.71 billion in 2025, turning profitable with net income of $313.75 million. Analyst consensus is strongly bullish with a $429.50 price target, supported by positive news on drug pipelines and AI partnerships.
Outlook remains positive driven by expanding product portfolio and strategic collaborations, though risks include clinical trial outcomes and high valuation multiples. Earnings beats in recent quarters reinforce growth trajectory, but dependence on key drug Amvuttra and competitive pressures warrant monitoring for sustained shareholder value.
U.S. Bancorp (USB) trades at $62.41, up 0.82% with a bullish technical outlook supported by moving averages. The stock shows strong fundamentals with three consecutive quarterly earnings beats, a P/E of 13.08, and net income margin of 27.04%. Recent developments include the launch of Enhanced Payments for small businesses and a planned dividend increase following successful stress test results.
The outlook remains positive with analyst consensus targeting $67.00 (7.4% upside). Key opportunities include sustained earnings growth and dividend reliability, while risks involve negative cash flow trends and rising debt-to-asset ratios. The stock presents a balanced risk-reward profile for value-oriented investors seeking financial sector exposure.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Alnylam Pharmaceuticals, Inc.
Alnylam Pharmaceuticals is a leader in the study of RNA interference (RNAi) therapeutics. RNAi is a naturally occurring biological pathway within cells for sequence-specific silencing and regulation of gene expression. Alnylam has five drugs on the market: Onpattro and Amvuttra for hATTR amyloidosis, Givlaari for acute hepatic porphyria, Oxlumo for primary hyperoxaluria type 1, and Leqvio for hypercholesterolemia.
Read more on ALNY →About US Bancorp
As a diversified financial-services provider, U.S. Bancorp is one of the nation's largest regional banks, with branches in well over 20 states, primarily in the Western and Midwestern United States. The bank offers many services, including retail banking, commercial banking, trust and wealth services, credit cards, mortgages, and other payments capabilities.
Read more on USB →
